GRCL News and Press, Gracell Biotechnologies Inc. From 06/20/23

2023-06-20 17:42:47 ET Gainers: 2U ( TWOU ) +7% . Silk Road Medical ( SILK ) +4% . ROC Energy Acquisition  ( ROC ) +4% . AXT ( AXTI ) +4% . CVB Financial ( CVBF ) +3% . Losers: LifeStance Health Group ( LFST ) ...

2023-06-20 10:07:39 ET Gainers: DICE Therapeutics ( DICE ) +38% . iCAD ( ICAD ) +17% . Nuwellis ( NUWE ) +14% . Valneva ( VALN ) +14% . Cano Health ( CANO ) +13% . Losers: Surgalign ( SRGA ) -72% . Gracel...

SAN DIEGO and SUZHOU and SHANGHAI, China, June 20, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of canc...

2023-06-13 15:29:56 ET Shares of Gracell Biotechnologies (NASDAQ: GRCL) were up 21.5% Tuesday afternoon. The healthcare stock rose for the second consecutive day, boosted by an analyst's upgrade, as well as by positive trial news. The stock is up more than 156% so far this year....

2023-06-13 08:20:35 ET Auddia ( AUUD ) -37% . Advanced Health Intelligence ( AHI ) -28% . Finch Therapeutics Group ( FNCH ) -22% . Asset Entities ( ASST ) -18% . Jin Medical International Ltd. ( ZJYL ) -16% on releasing new-generatio...

Gracell Biotechnologies Inc. (NASDAQ: GRCL) is one of today's top gainers. The company's shares are currently up 20% on the day to $4.8. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the ...

2023-06-12 13:17:32 ET Gainers: Asset Entities ( ASST ) +95% . Jin Medical International ( ZJYL ) +68% . Chinook Therapeutics ( KDNY ) +58% . Infobird ( IFBD ) +42% . Micromobility.com ( MCOM ) +39% . Freightos Limited ( CR...

2023-06-12 12:35:53 ET Gracell Biotechnologies ( NASDAQ: GRCL ) added ~20% on Monday after the Chinese biotech announced long-term follow-up data for its CAR-T cell therapy GC012F in relapsed/refractory B-cell non-Hodgkin’s Lymphoma. According to a presentation at the...

2023-06-11 08:30:00 ET Summary Shenzhen HighTide Therapeutics filed for an IPO on the Hong Kong Exchange to develop a portfolio of novel multifunctional drugs for metabolic and digestive diseases. Shanghai Fosun Pharma will partner with World Bank affiliate International Finance C...

Data on CD19/BCMA dual-targeting FasTCAR-T GC012F showed 100% overall response rate (ORR) and 66.7% 6-month complete response (CR) rate among treated patients, all with diffuse large B-cell lymphoma (DLBCL) subtype Data on GC012F for treatment of relapsed/refractory multiple myeloma (...